A5044969826- Inflammatory Bowel Disease
- Microscopic Colitis
- Diverticular Disease and Complications
- Eosinophilic Esophagitis
- Biosimilars and Bioanalytical Methods
- Anorectal Disease Treatments and Outcomes
- Primary Care and Health Outcomes
- Immunodeficiency and Autoimmune Disorders
- Colorectal Cancer Screening and Detection
- Healthcare Policy and Management
- Autoimmune and Inflammatory Disorders
- Autoimmune and Inflammatory Disorders Research
- Chronic Disease Management Strategies
- Adolescent and Pediatric Healthcare
- Pharmaceutical studies and practices
- Pregnancy and Medication Impact
- Lymphoma Diagnosis and Treatment
- Gastrointestinal disorders and treatments
- Colorectal Cancer Surgical Treatments
- Intramuscular injections and effects
- Pancreatitis Pathology and Treatment
- Clostridium difficile and Clostridium perfringens research
- Gastric Cancer Management and Outcomes
- Urticaria and Related Conditions
- Colorectal Cancer Treatments and Studies
Mount Sinai Hospital
2018-2024
Icahn School of Medicine at Mount Sinai
2004-2023
Mount Sinai Hospital
2004-2021
Cornell University
2014-2018
Presbyterian Hospital
2014-2018
University of Pennsylvania
2018
Weill Cornell Medicine
2017
Penn Presbyterian Medical Center
2016
New York Hospital Queens
2014-2015
NewYork–Presbyterian Hospital
2014-2015
OBJECTIVES Patients with extensive, longstanding chronic ulcerative or Crohn's colitis face greater risks of developing colorectal cancer. Current standard surveillance relies on detecting dysplasia using random sampling at colonoscopy but may fail to detect in many patients. Dye spraying techniques have been reported aid otherwise subtle mucosal abnormalities the setting colitis. We prospectively compared dye-spray technique methylene blue colonoscopic dysplasia. METHODS One hundred fifteen...
IgA-reactive E. coli in Crohn’s disease–associated spondyloarthritis link mucosal immunity and systemic inflammation.
Abstract Background and Aims Quality of life in patients with active Crohn’s disease may be significantly reduced. We evaluated the effects upadacitinib induction maintenance therapy on fatigue, quality life, work productivity phase 3 trials U-EXCEL, U-EXCEED, U-ENDURE. Methods Clinical responders to 45 mg U-EXCEL U-EXCEED were re-randomised 1:1:1 30 mg, 15 or placebo for 52 weeks Clinically meaningful improvements Inflammatory Bowel Disease Questionnaire [IBDQ] response, IBDQ remission,...
The hepatic venous pressure gradient (HVPG) is becoming increasingly used clinically. It useful in the differential diagnosis of portal hypertension and provides a prognostic index cirrhotic patients. Performance serial measurements has been shown to be guiding pharmacological therapy variceal hemorrhage. technique safe perform; however, many patients are anxious reluctant undergo measurements. effects sedatives on have not yet defined. objective this study was evaluate midazolam HVPG....
Cerebral venous thrombosis (CVT) is a rare but devastating complication of inflammatory bowel disease (IBD). Here we describe six IBD patients with cerebral thrombosis. The presented hours to days headache and were found have on imaging. Four the had ulcerative colitis two Crohn's disease. All treated therapeutic anticoagulation. There deaths; one patient became comatose died despite anticoagulation while other recovered well from sinus after perforation 3 weeks later. This case series...
Infliximab (IFX) is commonly used in patients with inflammatory bowel disease. One common side effect of IFX an acute infusion reaction. Despite the lack evidence supporting their use, clinicians use various premedications to prevent reactions. We evaluated effectiveness prevention reactions.A retrospective cohort study was performed identifying a diagnosis disease who received at our institution. Information about each recorded, including dose, rate, premedications, and any Infusions were...
Abstract Background Upadacitinib (UPA) demonstrated efficacy and safety in the phase 3 U-EXCEED (NCT03345836) U-EXCEL (NCT03345849) induction, U-ENDURE (NCT03345823) maintenance trials patients (pts) with moderately to severely active Crohn’s disease (CD). We evaluated impact of UPA on health-related quality life (QoL) pts CD. Methods Clinical responders 45 mg (UPA45) induction were re-randomised at Week 12 (1:1:1) 15 (UPA15), 30 (UPA30), or placebo (PBO) for 52 weeks treatment U-ENDURE;...
Even in the biologic era, corticosteroid dependency IBD patients is common and causes a lot of morbidity, but methods withdrawal are not well described.To assess effectiveness method.Twelve (10 men, 2 women; 6 ulcerative colitis, Crohn's disease), median age 53.5 years (range 29-75) were included. with quiescent disease refractory to conventional weaning transitioned oral dexamethasone, educated about symptoms syndrome (CWS) weaned under supervision an endocrinologist. When failed wean...
Case Report: We present two cases of patients with well-controlled Crohn's disease (CD) treated adalimumab who developed severe tumor necrosis factor alpha (TNFa) inhibitor induced psoriasis (TNFIP). The first is a 23 year old woman presented psoriatic lesions on her arms, legs and back 16 months after initiation adalimumab. Topical steroids had no effect skin findings continued to worsen. Given the hands, she was unable work found debilitating. subsequently stopped transitioned Ustekinumab,...
Feagins, Linda A. MD1; Gold, Stephanie MD2; Steinlauf, Adam F. and the FDA-Related Matters Committee of American College Gastroenterology Author Information